×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GERN – geron corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GERN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
11:50 pm
gern
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting [Yahoo! Finance]
12/11
05:42 pm
gern
Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines [Seeking Alpha]
Low
Report
Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On The Sidelines [Seeking Alpha]
12/11
08:27 am
gern
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation [Yahoo! Finance]
Medium
Report
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation [Yahoo! Finance]
12/11
08:00 am
gern
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Medium
Report
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
12/9
11:08 am
gern
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
12/9
11:08 am
gern
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Geron (NASDAQ:GERN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
12/8
08:02 am
gern
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
Medium
Report
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
12/4
12:20 pm
gern
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Neutral
Report
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/7
04:11 pm
gern
Form 10-Q GERON CORP For: Sep 30
Medium
Report
Form 10-Q GERON CORP For: Sep 30
11/5
07:06 am
gern
Form 8-K GERON CORP For: Nov 05
Medium
Report
Form 8-K GERON CORP For: Nov 05
10/20
06:50 pm
gern
Form 3 GERON CORP For: Oct 20 Filed by: ElNawawi Ahmed
Low
Report
Form 3 GERON CORP For: Oct 20 Filed by: ElNawawi Ahmed
10/20
05:35 pm
gern
Form 4 GERON CORP For: Oct 20 Filed by: ElNawawi Ahmed
Low
Report
Form 4 GERON CORP For: Oct 20 Filed by: ElNawawi Ahmed
10/14
08:17 am
gern
Form 8-K GERON CORP For: Oct 10
Low
Report
Form 8-K GERON CORP For: Oct 10
10/1
04:38 pm
gern
Form 4 GERON CORP For: Sep 30 Filed by: Spiegel Robert J.
Low
Report
Form 4 GERON CORP For: Sep 30 Filed by: Spiegel Robert J.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/30
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
13.6%
3/17 Geron Co. (NASDAQ: GERN) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock. 10.5%
3/19 GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm 10.2%
3/20 Geron Co. (NASDAQ: GERN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 8.9%
10/10 Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 7.0%
1/13 Form 4 GERON CORP For: Jan 10 Filed by: O'Farrell Elizabeth G. 6.7%
3/12 Q4/2019 12/31/2019 EPS -0.150 ZacksConsensus -0.200 ActVsEst 0.050 - Beat 6.5%
8/15 Geron Co. (NASDAQ: GERN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 6.1%
8/8 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 5.8%
3/20 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm 5.8%
3/17 Geron Co. (NASDAQ: GERN) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock. 10.5%
3/19 GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm 10.2%
3/20 Geron Co. (NASDAQ: GERN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 8.9%
10/10 Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 7.0%
1/13 Form 4 GERON CORP For: Jan 10 Filed by: O'Farrell Elizabeth G. 6.7%
3/12 Q4/2019 12/31/2019 EPS -0.150 ZacksConsensus -0.200 ActVsEst 0.050 - Beat 6.5%
8/15 Geron Co. (NASDAQ: GERN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 6.1%
8/8 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 5.8%
3/20 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm 5.8%
TOP News Decliners
5/16
Geron Provides Imetelstat Program Update
-9.8%
3/5 Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -9.7%
9/3 Geron Co. (NASDAQ: GERN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -7.6%
3/15 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm -7.3%
6/17 Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress -6.4%
11/15 Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT [Yahoo! Finance News] -5.1%
8/22 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.9%
12/19 Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -4.7%
10/17 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.7%
1/30 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation (GERN) -4.4%
3/5 Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -9.7%
9/3 Geron Co. (NASDAQ: GERN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -7.6%
3/15 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm -7.3%
6/17 Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress -6.4%
11/15 Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT [Yahoo! Finance News] -5.1%
8/22 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.9%
12/19 Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -4.7%
10/17 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.7%
1/30 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation (GERN) -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: